Attached files
| file | filename |
|---|---|
| 8-K - 8-K - VERTEX PHARMACEUTICALS INC / MA | a10-18206_38k.htm |
| EX-1.1 - EX-1.1 - VERTEX PHARMACEUTICALS INC / MA | a10-18206_3ex1d1.htm |
| EX-25.1 - EX-25.1 - VERTEX PHARMACEUTICALS INC / MA | a10-18206_3ex25d1.htm |
Exhibit 12.1
Vertex Pharmaceuticals Incorporated
Computation of Ratio of Earnings to Fixed Charges
(Amounts in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
||||||
|
|
|
Year ended December 31, |
|
June 30, |
|
||||||||||||||
|
|
|
2009 |
|
2008 |
|
2007 |
|
2006 |
|
2005 |
|
2010 |
|
||||||
|
Loss from continuing operations before cumulative effect of a change in accounting principle |
|
$ |
(642,178 |
) |
$ |
(459,851 |
) |
$ |
(391,279 |
) |
$ |
(207,937 |
) |
$ |
(203,417 |
) |
$ |
(365,277 |
) |
|
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Interest expense and amortization of deferred issuance costs |
|
13,192 |
|
13,471 |
|
2,285 |
|
7,955 |
|
17,326 |
|
7,638 |
|
||||||
|
Appropriate rental obligations |
|
17,827 |
|
14,901 |
|
13,520 |
|
15,938 |
|
14,736 |
|
9,765 |
|
||||||
|
Total fixed charges |
|
$ |
31,019 |
|
$ |
28,372 |
|
$ |
15,805 |
|
$ |
23,893 |
|
$ |
32,062 |
|
$ |
17,403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Loss from continuing operations before cumulative effect of a change in accounting principle, plus fixed charges |
|
$ |
(611,159 |
) |
$ |
(431,479 |
) |
$ |
(375,474 |
) |
$ |
(184,044 |
) |
$ |
(171,355 |
) |
$ |
(347,874 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Ratio of earnings to fixed charges |
|
* |
|
* |
|
* |
|
* |
|
* |
|
* |
|
||||||
|
* |
Due to the Company’s loss from continuing operations before cumulative effect of a change in accounting principle, earnings were insufficent to cover fixed charges by $365,277,000 for the six months ended June 30, 2010 and earnings were insufficent to cover fixed charges by $642,178,000, $459,851,000, $391,279,000, $207,937,000 and $203,417,000, respectively, for the years ended December 31, 2009, 2008, 2007, 2006 and 2005. |